

NEVRO CORP
Form 4
November 12, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
PLIAM NATHAN B

(Last) (First) (Middle)

C/O NEVRO CORP., 4040
CAMPBELL AVENUE

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEVRO CORP [NVRO]

3. Date of Earliest Transaction
(Month/Day/Year)
11/12/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|-----------------------|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 11/12/2014 | | C | | 1,272,841 (1) (2) | A (2) | 1,296,293 (1) | I | See footnotes (3) (4) |
| Common Stock | 11/12/2014 | | C | | 682,826 (1) (5) | A (5) | 1,979,119 (1) | I | See footnotes (3) (4) |
| Common Stock | 11/12/2014 | | C | | 191,314 (1) (6) | A (6) | 2,170,433 (1) | I | See footnotes (3) (4) |
| Common Stock | 11/12/2014 | | C | | 27,435 (1) (2) | A (2) | 27,940 (1) | I | See footnotes |

Edgar Filing: NEVRO CORP - Form 4

| | | | | | | | | |
|--------------|------------|---|-------------------------------------|---|------------|-------------------------------------|---|--|
| Common Stock | 11/12/2014 | C | 14,718 ⁽¹⁾ <u>(5)</u> | A | <u>(5)</u> | 42,658 ⁽¹⁾ <u>(1)</u> | I | <u>(7)</u> <u>(4)</u> See footnotes <u>(7)</u> <u>(4)</u> |
| Common Stock | 11/12/2014 | C | 4,123 ⁽¹⁾ <u>(6)</u> | A | <u>(6)</u> | 46,781 ⁽¹⁾ <u>(1)</u> | I | <u>(7)</u> <u>(4)</u> See footnotes <u>(7)</u> <u>(4)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Series A Preferred Stock | <u>(2)</u> | 11/12/2014 | | C | 1,272,841 ⁽¹⁾ <u>(1)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 1,272,841 ⁽¹⁾ <u>(2)</u> |
| Series B Preferred Stock | <u>(5)</u> | 11/12/2014 | | C | 682,826 ⁽¹⁾ <u>(1)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 682,826 ⁽¹⁾ <u>(5)</u> |
| Series C Preferred Stock | <u>(6)</u> | 11/12/2014 | | C | 191,314 ⁽¹⁾ <u>(1)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 191,314 ⁽¹⁾ <u>(6)</u> |
| Series A Preferred Stock | <u>(2)</u> | 11/12/2014 | | C | 27,435 ⁽¹⁾ <u>(2)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 27,435 ⁽¹⁾ <u>(2)</u> |
| Series B Preferred Stock | <u>(5)</u> | 11/12/2014 | | C | 14,718 ⁽¹⁾ <u>(5)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 14,718 ⁽¹⁾ <u>(5)</u> |
| Series C Preferred Stock | <u>(6)</u> | 11/12/2014 | | C | 4,123 ⁽¹⁾ <u>(6)</u> | <u>(8)</u> <u>(9)</u> | Common Stock 4,123 ⁽¹⁾ <u>(6)</u> |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| PLIAM NATHAN B C/O NEVRO CORP. 4040 CAMPBELL AVENUE MENLO PARK, CA 94025 | X | | | |

Signatures

/s/ Nathan Pliam 11/12/2014

Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects a 1-for-24 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
- (2) Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- (3) Shares held by Bay City Capital Fund IV, L.P.
Bay City Capital Management IV ("BCCM IV") is the General Partner of Bay City Capital Fund IV, L.P. ("BCCF") and Bay City Capital Fund IV Co-Investment Fund, L.P. ("BCCF Co-Investment Fund") and Bay City Capital LLC ("BCC") is the Manager of BCCM IV.
- (4) BCCM IV and BCC may be deemed to have sole voting and investment power over the shares held by BCCF and BCCF Co-Investment Fund however hold no securities of the Issuer directly. Nathan Pliam, a Venture Partner of BCC, is a member of the Issuer's Board of Directors. Mr. Pliam disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- (5) Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- (6) Each share of Series C Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- (7) Shares held by Bay City Capital Fund IV Co-Investment Fund, L.P.
- (8) The shares are immediately convertible.
- (9) The shares do not have an expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.